276 related articles for article (PubMed ID: 32725406)
1. Novel Approaches to the Systemic Management of Uveal Melanoma.
Khan S; Carvajal RD
Curr Oncol Rep; 2020 Jul; 22(10):104. PubMed ID: 32725406
[TBL] [Abstract][Full Text] [Related]
2. Update on Metastatic Uveal Melanoma: Progress and Challenges.
Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of the emerging molecular biology of uveal melanoma.
Patel M; Smyth E; Chapman PB; Wolchok JD; Schwartz GK; Abramson DH; Carvajal RD
Clin Cancer Res; 2011 Apr; 17(8):2087-100. PubMed ID: 21444680
[TBL] [Abstract][Full Text] [Related]
4. Uveal melanoma: In the era of new treatments.
Wespiser M; Neidhardt E; Negrier S
Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
[TBL] [Abstract][Full Text] [Related]
5. Uveal melanoma.
Spagnolo F; Caltabiano G; Queirolo P
Cancer Treat Rev; 2012 Aug; 38(5):549-53. PubMed ID: 22270078
[TBL] [Abstract][Full Text] [Related]
6. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
[TBL] [Abstract][Full Text] [Related]
7. Updates in the Management of Uveal Melanoma.
Barbi M; Carvajal RD; Devoe CE
Cancer J; 2024 Mar-Apr 01; 30(2):92-101. PubMed ID: 38527262
[TBL] [Abstract][Full Text] [Related]
8. Metastatic disease from uveal melanoma: treatment options and future prospects.
Carvajal RD; Schwartz GK; Tezel T; Marr B; Francis JH; Nathan PD
Br J Ophthalmol; 2017 Jan; 101(1):38-44. PubMed ID: 27574175
[TBL] [Abstract][Full Text] [Related]
9. Metastatic uveal melanoma: biology and emerging treatments.
Woodman SE
Cancer J; 2012; 18(2):148-52. PubMed ID: 22453016
[TBL] [Abstract][Full Text] [Related]
10. Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.
Komatsubara KM; Manson DK; Carvajal RD
Future Oncol; 2016 Jun; 12(11):1331-44. PubMed ID: 27044592
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
12. Uveal melanoma: the good and the bad.
Hadden PW
Clin Exp Ophthalmol; 2008 Apr; 36(3):203. PubMed ID: 18412585
[No Abstract] [Full Text] [Related]
13. The treatment of advanced melanoma: Current approaches and new challenges.
Boutros A; Croce E; Ferrari M; Gili R; Massaro G; Marconcini R; Arecco L; Tanda ET; Spagnolo F
Crit Rev Oncol Hematol; 2024 Apr; 196():104276. PubMed ID: 38295889
[TBL] [Abstract][Full Text] [Related]
14. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
Liu AW; Wei AZ; Maniar AB; Carvajal RD
Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
[TBL] [Abstract][Full Text] [Related]
15. Uveal melanoma: laboratory advances and new frontiers in patient care.
Xu TT; Moser JC; Dalvin LA
Curr Opin Ophthalmol; 2021 May; 32(3):301-308. PubMed ID: 33606406
[TBL] [Abstract][Full Text] [Related]
16. Biology of advanced uveal melanoma and next steps for clinical therapeutics.
Luke JJ; Triozzi PL; McKenna KC; Van Meir EG; Gershenwald JE; Bastian BC; Gutkind JS; Bowcock AM; Streicher HZ; Patel PM; Sato T; Sossman JA; Sznol M; Welch J; Thurin M; Selig S; Flaherty KT; Carvajal RD
Pigment Cell Melanoma Res; 2015 Mar; 28(2):135-47. PubMed ID: 25113308
[TBL] [Abstract][Full Text] [Related]
17. Tebentafusp for the treatment of metastatic uveal melanoma.
Schank TE; Hassel JC
Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
[TBL] [Abstract][Full Text] [Related]
18. From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
Synoradzki KJ; Paduszyńska N; Solnik M; Toro MD; Bilmin K; Bylina E; Rutkowski P; Yousef YA; Bucolo C; Zweifel SA; Reibaldi M; Fiedorowicz M; Czarnecka AM
Curr Oncol; 2024 Feb; 31(2):778-800. PubMed ID: 38392052
[TBL] [Abstract][Full Text] [Related]
19. The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).
Chua V; Mattei J; Han A; Johnston L; LiPira K; Selig SM; Carvajal RD; Aplin AE; Patel SP
Clin Cancer Res; 2021 Jan; 27(1):28-33. PubMed ID: 33060121
[TBL] [Abstract][Full Text] [Related]
20. Advances in the clinical management of uveal melanoma.
Carvajal RD; Sacco JJ; Jager MJ; Eschelman DJ; Olofsson Bagge R; Harbour JW; Chieng ND; Patel SP; Joshua AM; Piperno-Neumann S
Nat Rev Clin Oncol; 2023 Feb; 20(2):99-115. PubMed ID: 36600005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]